
Midatech Pharma plc MTP
Annual report 2024
added 03-21-2026
Midatech Pharma plc P/S Ratio 2011-2026 | MTP
Annual P/S Ratio Midatech Pharma plc
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 137 | 0.0609 | 0.035 | 8.8 | 27.4 | 6 | 35.1 | - | - | - | - |
All numbers in GBP currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 137 | 0.035 | 30.6 |
P/S Ratio of other stocks in the Biotechnology industry
| Issuer | P/S Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
1.75 | - | 2.43 % | $ 254 M | ||
|
Heron Therapeutics
HRTX
|
1.28 | $ 0.8 | 2.7 % | $ 133 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
1.73 | $ 19.23 | -1.38 % | $ 899 M | ||
|
Altimmune
ALT
|
7.76 K | $ 3.44 | 2.99 % | $ 303 M | ||
|
Aytu BioScience
AYTU
|
0.237 | $ 2.63 | 0.77 % | $ 16.5 M | ||
|
I-Mab
IMAB
|
94.1 | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
5.53 | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
1.96 K | - | 2.54 % | $ 160 B | ||
|
Ascendis Pharma A/S
ASND
|
947 | $ 218.06 | -1.72 % | $ 5 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.39 K | - | -1.52 % | $ 24.7 M | ||
|
Incyte Corporation
INCY
|
3.79 | $ 90.45 | -0.36 % | $ 17.7 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
65.5 | - | - | $ 26.5 M | ||
|
Inovio Pharmaceuticals
INO
|
265 | $ 1.61 | 1.9 % | $ 35.7 M | ||
|
Aeterna Zentaris
AEZS
|
7.87 | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
0.099 | - | -10.17 % | $ 12.2 K | ||
|
Acorda Therapeutics
ACOR
|
0.142 | - | -24.86 % | $ 820 K | ||
|
Albireo Pharma
ALBO
|
13.3 | - | -0.23 % | $ 916 M | ||
|
Acasti Pharma
ACST
|
0.203 | - | 4.01 % | $ 150 M | ||
|
Институт стволовых клеток человека
ISKJ
|
2.61 | - | - | - | ||
|
Inventiva S.A.
IVA
|
128 | $ 6.08 | 5.19 % | $ 138 M | ||
|
Adverum Biotechnologies
ADVM
|
76.4 | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
25.8 | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
144 | - | -9.65 % | $ 45.9 M | ||
|
Ayala Pharmaceuticals
AYLA
|
11.2 | - | - | $ 7.46 M | ||
|
Cullinan Management
CGEM
|
35.1 | $ 12.84 | 0.78 % | $ 774 M | ||
|
BioDelivery Sciences International
BDSI
|
1.85 | - | -4.8 % | $ 255 M | ||
|
BeiGene, Ltd.
BGNE
|
66.4 | - | 0.49 % | $ 251 B | ||
|
KalVista Pharmaceuticals
KALV
|
11.4 | $ 16.6 | -2.35 % | $ 824 M | ||
|
Kamada Ltd.
KMDA
|
2.61 | $ 8.2 | -0.61 % | $ 260 M | ||
|
Calithera Biosciences
CALA
|
98.5 | - | -10.95 % | $ 876 K | ||
|
Cara Therapeutics
CARA
|
2.58 | - | -3.03 % | $ 260 M | ||
|
ChemoCentryx
CCXI
|
0.0564 | - | - | $ 3.74 B | ||
|
Karyopharm Therapeutics
KPTI
|
0.000503 | $ 6.66 | -12.71 % | $ 812 K | ||
|
Keros Therapeutics
KROS
|
2.1 | $ 11.24 | 2.55 % | $ 418 M | ||
|
Checkpoint Therapeutics
CKPT
|
3.91 K | - | - | $ 169 M | ||
|
Clovis Oncology
CLVS
|
1.55 | - | -7.23 % | $ 13 M | ||
|
Aeglea BioTherapeutics
AGLE
|
489 | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
281 | - | - | $ 867 M | ||
|
Longeveron
LGVN
|
14.1 K | $ 0.95 | -2.71 % | $ 16.7 B | ||
|
Denali Therapeutics
DNLI
|
7.68 | $ 21.09 | 4.56 % | $ 3.47 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
24.5 | $ 4.42 | 4.25 % | $ 734 M |